A Predictive Score for the Ischemic Etiology of a Transient Diplopia (VASCO-DIP)
ConditionDiplopia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFondation Ophtalmologique Adolphe de Rothschild
About this trial
The transient diplopias (TD) is defined by a short diplopia. Their etiology may be ophthalmological, neurological non-ischemic or of ischemic origin.
The difficulty is to recognize an ischemic mechanism which imposes emergency cares.
A clinical score could help the clinician to recognize the etiology of the TD .
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Transient diplopia (i.e. less than 24 hours) during the last 8 days
Disqualifiers
None
Trial population
Adults having had a transient diplopia during the last 8 days and seen at the fondation ophtalmologique Adolphe de Rothschild
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Clinical, ophthalmological and neurological evaluation
Other interventionClinical : questionnaire about the symptoms and about the vascular risk factors Imagery :Cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, Biology : blood count, erythrocytes sedimentation rate, C reactive protein Ophthalomogy : visual field, optical coherence tomography, retinography
Treatment groups
220 Participants
are divided into 1 treatment groupGroup A: Eligible patients1 intervention
Trial outcomes
Primary outcomes
1
Etiology, ischemic or not, of the initial transient diplopia
Questionnaire about the symptoms and about the vascular risk factors, cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, blood count, erythrocytes sedimentation rate, C reactive protein, visual field, optical coherence tomography, retinography and a new evaluation after 3 months.
Time frame
3 monthsSecondary outcomes
1
Incidence of new transient diplopia ischemic attacks during the 3 months of follow-up
Questionnaire about the symptoms and about the vascular risk factors, cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, blood count, erythrocytes sedimentation rate, C reactive protein, visual field, optical coherence tomography, retinography and a new evaluation after 3 months.
Time frame
3 months2
Incidence of diplopia ischemic strokes during the 3 months of follow-up
Questionnaire about the symptoms and about the vascular risk factors, cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, blood count, erythrocytes sedimentation rate, C reactive protein, visual field, optical coherence tomography, retinography and a new evaluation after 3 months.
Time frame
3 months3
Incidence of transient ischemic attacks, visual or not visual, during the 3 months of follow-up
Questionnaire about the symptoms and about the vascular risk factors, cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, blood count, erythrocytes sedimentation rate, C reactive protein, visual field, optical coherence tomography, retinography and a new evaluation after 3 months.
Time frame
3 months4
Incidence of ischemic strokes, visual or not visual, during the 3 months of follow-up
Questionnaire about the symptoms and about the vascular risk factors, cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, blood count, erythrocytes sedimentation rate, C reactive protein, visual field, optical coherence tomography, retinography and a new evaluation after 3 months.
Time frame
3 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov